TAU subjects who had been prescribed medications at baseline that were contraindicated based on the individual subject 's genotype ( i.e. , red bin ) had almost no improvement ( @ % ) in depressive symptoms measured by HAMD-@ at week @ , which was far less than the @ % improvement ( p = @ ) in the pharmacogenomic guided subjects who started on a red bin medication and the @ % improvement in GeneSight subjects overall ( p = @ ) .